Skip to main content
SpringerLink
Log in

Docetaxel

  • Chapter
  • First Online:
Drug Management of Prostate Cancer

Abstract

Despite the widespread use of prostate-specific antigen (PSA) for prostate cancer screening, many patients still present with or develop evidence of progressive, metastatic, or recurrent disease. First-line treatment for these patients has long been androgen deprivation therapy (ADT). Initial ADT usually consists of medical or surgical castration, but these agents fail in a median of 18–24 months, as patients develop castration-resistant prostate cancer (CRPC). Treatment options at this point in disease progression traditionally provided palliation only. Secondary hormonal manipulations can produce PSA responses, and the standard chemotherapy combination of mitoxantrone and prednisone can ameliorate symptoms but neither approach ever produced better survival than prednisone alone. Docetaxel-based chemotherapy is the first treatment regimen demonstrated to increase survival in patients with CRPC. The exact timing of treatment in the spectrum of CRPC and duration of docetaxel therapy remains controversial. This chapter reviews the use of docetaxel in prostate cancer, discusses the optimal timing of chemotherapy, and highlights the future directions in taxane-combination therapy involving novel investigational uses.

An erratum to this chapter can be found at http://dx.doi.org/10.1007/978-1-60327-829-4_37

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: Cancer J Clin 2008;58(2):71–96.

    Article  Google Scholar 

  2. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25(12):1596–605.

    Article  PubMed  CAS  Google Scholar 

  3. Lucas A, Petrylak DP. The case for early chemotherapy for the treatment of metastatic disease. J Urol 2006;176(6 Pt 2): S72–5.

    Article  PubMed  CAS  Google Scholar 

  4. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17(8):2506–13.

    PubMed  CAS  Google Scholar 

  5. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14(6):1756–64.

    PubMed  CAS  Google Scholar 

  6. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981;91(2 Pt 1):479–87.

    Article  PubMed  CAS  Google Scholar 

  7. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277(5698):665–7.

    Article  PubMed  CAS  Google Scholar 

  8. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980;77(3):1561–5.

    Article  PubMed  CAS  Google Scholar 

  9. Foa R, Norton L, Seidman AD. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int J Clin Lab Res 1994;24(1):6–14.

    Article  PubMed  CAS  Google Scholar 

  10. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993;72(8):2457–60.

    Article  PubMed  CAS  Google Scholar 

  11. Tew KD, Glusker JP, Hartley-Asp B, Hudes G, Speicher LA. Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmcol Ther 1992;56(3):323–39.

    Article  CAS  Google Scholar 

  12. Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 1992;52(16):4433–40.

    PubMed  CAS  Google Scholar 

  13. Haas N, Roth B, Garay C, et al. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology 2001;58(1):59–64.

    Article  PubMed  CAS  Google Scholar 

  14. Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 1992;147(3 Pt 2):931–4.

    PubMed  CAS  Google Scholar 

  15. Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992;10(11):1754–61.

    PubMed  CAS  Google Scholar 

  16. Hudes GR, Obasaju C, Chapman A, Gallo J, McAleer C, Greenberg R. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer. Semin Oncol 1995;22(3 Suppl 6):6–11.

    PubMed  CAS  Google Scholar 

  17. Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997;15(9):3156–63.

    PubMed  CAS  Google Scholar 

  18. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991;83(4):288–91.

    Article  PubMed  CAS  Google Scholar 

  19. Vidensek N, Lim P, Campbell A, Carlson C. Taxol content in bark, wood, root, leaf, twig, and seedling from several Taxus species. J Nat Prod1990;53(6):1609–10.

    Article  PubMed  CAS  Google Scholar 

  20. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991;51(18):4845–52.

    PubMed  CAS  Google Scholar 

  21. Vogel M, Hilsenbeck SG, Depenbrock H, et al. Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer 1993;29A(14):2009–14.

    Article  PubMed  CAS  Google Scholar 

  22. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, Andre S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995;22(2 Suppl 4):3–16.

    CAS  Google Scholar 

  23. Budman DR, Calabro A, Kreis W. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 2002;13(10):1011–6.

    Article  PubMed  CAS  Google Scholar 

  24. Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997;79(2):196–202.

    Article  PubMed  CAS  Google Scholar 

  25. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999;26(5 Suppl 17):14–8.

    PubMed  CAS  Google Scholar 

  26. Petrylak DP, Macarthur RB, O’Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999;17(3):958–67.

    PubMed  CAS  Google Scholar 

  27. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 1999;10(1):33–8.

    Article  PubMed  CAS  Google Scholar 

  28. Petrylak DP, Macarthur R, O’Connor J, et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 1999;26(5 Suppl 17):28–33.

    PubMed  CAS  Google Scholar 

  29. Savarese D, Taplin ME, Halabi S, Hars V, Kreis W, Vogelzang N. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. Semin Oncol 1999;26(5 Suppl 17):39–44.

    PubMed  CAS  Google Scholar 

  30. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004;351(15):1502–12.

    Article  PubMed  CAS  Google Scholar 

  31. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242–5.

    Article  PubMed  CAS  Google Scholar 

  32. Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19(10):1749–53.

    Article  PubMed  CAS  Google Scholar 

  33. Saad F, Ruether D, Ernst S, et al. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. BJU Int 2008;102(5):551–5.

    Article  PubMed  CAS  Google Scholar 

  34. Slaviero KA, Clarke SJ, McLachlan AJ, Blair EY, Rivory LP. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 2004;57(1):44–53.

    Article  PubMed  CAS  Google Scholar 

  35. Hainsworth JD. Practical aspects of weekly docetaxel administration schedules. Oncologist 2004;9(5):538–45.

    Article  PubMed  CAS  Google Scholar 

  36. Petrylak DP. Chemotherapy for androgen-independent prostate cancer. World J Urol 2005;23(1):10–3.

    Article  PubMed  CAS  Google Scholar 

  37. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 2004;351(15):1513–20.

    Article  PubMed  CAS  Google Scholar 

  38. Berry DL, Moinpour CM, Jiang CS, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 2006;24(18):2828–35.

    Article  PubMed  CAS  Google Scholar 

  39. Petrylak DP. New paradigms for advanced prostate cancer. Rev Urol 2007;9(Suppl 2):S3–12.

    PubMed  Google Scholar 

  40. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74(4):609–19.

    Article  PubMed  CAS  Google Scholar 

  41. Perlman H, Zhang X, Chen MW, Walsh K, Buttyan R. An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death Differ 1999;6(1):48–54.

    Article  PubMed  CAS  Google Scholar 

  42. Eigl BJ, Eggener SE, Baybik J, et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 2005;11(13):4905–11.

    Article  PubMed  CAS  Google Scholar 

  43. Tang Y, Khan MA, Goloubeva O, et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 2006;12(1):169–74.

    Article  PubMed  CAS  Google Scholar 

  44. Hussain A, Dawson N, Amin P, et al. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol 2005;23(12):2789–96.

    Article  PubMed  CAS  Google Scholar 

  45. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002;168(6):2439–43.

    Article  PubMed  CAS  Google Scholar 

  46. Hamberg P, Verhagen PC, de Wit R. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer 2008;44(9):1193–7.

    Article  PubMed  CAS  Google Scholar 

  47. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007;13(21):6396–403.

    Article  PubMed  CAS  Google Scholar 

  48. Oudard S, Banu E, Scotte F, et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007;18(11):1828–33.

    Article  PubMed  CAS  Google Scholar 

  49. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med 1971;285(21):1182–6.

    Article  PubMed  CAS  Google Scholar 

  50. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61(8):3369–72.

    PubMed  CAS  Google Scholar 

  51. Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005;23(6):1295–311.

    Article  PubMed  CAS  Google Scholar 

  52. Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008;54(5):1089–94.

    Article  PubMed  Google Scholar 

  53. Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008;57(12):1849–59.

    Article  PubMed  CAS  Google Scholar 

  54. Sanborn SL, Cooney MM, Dowlati A, et al. Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest New Drugs 2008;26(4):355–62.

    Article  PubMed  CAS  Google Scholar 

  55. Ning Y, Arlen P, Fulley J, et al. Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (DOC) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). J Clin Oncol 2008;26:abstr 5000.

    Google Scholar 

  56. Cumashi A, Tinari N, Rossi C, et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008;270(2):229–33.

    Article  PubMed  CAS  Google Scholar 

  57. Guerin O, Formento P, Lo Nigro C, et al. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 2008;134(1):51–7.

    Article  PubMed  CAS  Google Scholar 

  58. George D, Liu G, Wilding G, et al. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone refractor prostate cancer (mHRPC) – preliminary results. J Clin Oncol 2008;26:abstr 5131.

    Google Scholar 

  59. ClinicalTrials.gov. Accessed 2008, at http://www.clinicaltrials.gov

  60. Wang YR, Wigington DP, Strugnell SA, Knutson JC. Growth inhibition of cancer cells by an active metabolite of a novel vitamin D prodrug. Anticancer Res 2005;25(6B):4333–9.

    PubMed  CAS  Google Scholar 

  61. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res 2000;60(4):779–82.

    PubMed  CAS  Google Scholar 

  62. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001;7(4):1043–51.

    PubMed  CAS  Google Scholar 

  63. Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 2001;28(4 Suppl 15):49–55.

    Article  PubMed  CAS  Google Scholar 

  64. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25(6):669–74.

    Article  PubMed  CAS  Google Scholar 

  65. Bagnato A, Rosano L. The endothelin axis in cancer. Int J Biochem Cell Biol 2008;40(8):1443–51.

    Article  PubMed  CAS  Google Scholar 

  66. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006;12(20 Pt 2):6296s–300s.

    Article  PubMed  CAS  Google Scholar 

  67. Jimeno A, Carducci M. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther 2005;5(3):419–27.

    Article  PubMed  CAS  Google Scholar 

  68. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21(4):679–89.

    Article  PubMed  CAS  Google Scholar 

  69. Banerjee S, Hussain M, Wang Z, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007;67(8):3818–26.

    Article  PubMed  CAS  Google Scholar 

  70. Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994;263(5146):526-9.

    Article  PubMed  CAS  Google Scholar 

  71. Luo JL, Tan W, Ricono JM, et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007;446(7136):690–4.

    Article  PubMed  CAS  Google Scholar 

  72. Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 2008;7(7):2160–9.

    Article  PubMed  CAS  Google Scholar 

  73. Dreicer R, Petrylak D, Agus D, Webb I, Roth B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 2007;13(4):1208–15.

    Article  PubMed  CAS  Google Scholar 

  74. Cao W, Shiverick KT, Namiki K, et al. Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. World J Urol 2008;26(5):509–16.

    Article  PubMed  CAS  Google Scholar 

  75. Morris M, Beekman K, Kelly W, et al. Phase II study of bortezomib for castrate metastatic prostate cancer. Proc Am Soc Clin Oncol 2005;23:411S(abstract 4633).

    Google Scholar 

  76. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22(11):2108–21.

    Article  PubMed  CAS  Google Scholar 

  77. Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22(11):2122–32.

    Article  PubMed  CAS  Google Scholar 

  78. Kaufman H, Wang W, Manola J, et al. Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: follow up clinical results from ECOG 7897. Proc Am Soc Clin Oncol 2005;24:4501a.

    Google Scholar 

  79. Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12(4):1260–9.

    Article  PubMed  CAS  Google Scholar 

  80. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008;14(11):3536–44.

    Article  PubMed  CAS  Google Scholar 

  81. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172(3):910–4.

    Article  PubMed  Google Scholar 

  82. Pickles T, Morgan S, Morton G, Souhami L, Warde P, Lukka H. Adjuvant radiotherapy following radical prostatectomy: Genito-Urinary Radiation Oncologists of Canada Consensus Statement. Can Urol Assoc J (Journal de l’Association des urologues du Canada) 2008;2(2):95–9.

    Google Scholar 

  83. Sonpavde G, Chi KN, Powles T, et al. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer 2007;110(12):2628–39.

    Article  PubMed  CAS  Google Scholar 

  84. Carson CC III, Zincke H, Utz DC, Cupps RE, Farrow GM. Radical prostatectomy after radiotherapy for prostatic cancer. J Urol 1980;124(2):237–9.

    PubMed  Google Scholar 

  85. Garcia JA, Klein EA, Magi-Galluzzi C, Elson P, Triozzi P, Dreicer R. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin Cancer Res 2008;14(10):3052–9.

    Article  PubMed  CAS  Google Scholar 

  86. Hussain M, Smith DC, El-Rayes BF, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology 2003;61(4):774–80.

    Article  PubMed  Google Scholar 

  87. Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004;63(6):1138–42.

    Article  PubMed  Google Scholar 

  88. Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11(14):5233–40.

    Article  PubMed  CAS  Google Scholar 

  89. Garzotto M, Myrthue A, Higano CS, Beer TM. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol 2006;24(3):254–9.

    Article  PubMed  CAS  Google Scholar 

  90. Friedman J, Dunn RL, Wood D, et al. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 2008;179(3):911–5; discussion 5–6.

    Article  Google Scholar 

  91. Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008;180(2):565–70; discussion 70.

    Article  PubMed  CAS  Google Scholar 

  92. Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003;62(Suppl 1):55–62.

    Article  PubMed  Google Scholar 

  93. Eisenberger M, Kattan M, Kibel A, Sternberg C, Epstein J. Impact of central pathology review (CPR) of radical prostatectomy (RP) specimens for patient selection in the surgical adjuvant trial in prostate cancer (PCa) TAX-3501. J Clin Oncol 2008;26:abstr 5128.

    Google Scholar 

  94. Kibel AS, Rosenbaum E, Kattan MW, et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 2007;177(5):1777–81.

    Article  PubMed  CAS  Google Scholar 

  95. Montgomery B, Lavori P, Garzotto M, et al. Veterans Affairs Cooperative Studies Program Study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. Urology 2008;72(3):474–80.

    Article  PubMed  Google Scholar 

  96. Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997;3(12 Pt 1):2431–8.

    PubMed  CAS  Google Scholar 

  97. Kumar P, Perrotti M, Weiss R, et al. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol 2004;22(10):1909–15.

    Article  PubMed  CAS  Google Scholar 

  98. Perrotti M, Doyle T, Kumar P, et al. Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10). Urol Oncol 2008;26(3):276–80.

    Article  PubMed  CAS  Google Scholar 

  99. Ebrrahimi K, Ruckle H, Harper J, et al. Post prostatectomy multimodality adjuvant therapy for patients at high risk for prostate cancer relapse. In: American Urologic Association Annual Meeting, Orlando;2008.

    Google Scholar 

  100. Patel AR, Sandler HM, Pienta KJ. Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer. Clinical Genitourin Cancer 2005;4(3):212–4.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Columbia University Medical Center, New York, NY, USA

    Daniel P. Petrylak

Authors
  1. Courtney K. Phillips
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel P. Petrylak
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Oncology Branch, NIH National Cancer Institute, Rockville Pike 9000, Bethesda, 20892, Maryland, USA

    William D. Figg

  2. Medical Oncology Branch, NIH National Cancer Institute, Rockville Pike 9000, Bethesda, 20892, Maryland, USA

    Cindy H. Chau

  3. School of Medicine, Dept. Urology, University of California, San Francisco, Divisadero Street 1600, San Francisco, 94115, California, USA

    Eric J. Small

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Phillips, C.K., Petrylak, D.P. (2010). Docetaxel. In: Figg, W., Chau, C., Small, E. (eds) Drug Management of Prostate Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-60327-829-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-829-4_12

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-60327-831-7

  • Online ISBN: 978-1-60327-829-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation